67-4

17/90

complications of type 2 diabetes (UKPDS 35): prospec‑tive observational study. BMJ, 2000; 321: 405-412. 4) Gummesson A, Nyman E, Knutsson M, Karpefors M: Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes Obes Metab, 2017; 19: 1295-1305. 5) Ghosal S, Sinha B, Majumder M, Misra A: Estimation of effects of nationwide lockdown for containing coro‑navirus infection on worsening of glycosylated haemo‑globin and increase in diabetes-related complications: A simulation model using multivariate regression anal‑ysis. Diabetes Metab Syndr, 2020 Jul-Aug; 14: 319-323. 6) Verma A, Rajput R, Verma S, Balania VKB, Jangra B: Impact of lockdown in COVID 19 on glycemic control in patients with type 1 diabetes mellitus. Diabetes Metab Syndr, 2020; 14: 1213-1216. 7) Fernández E, Cortazar A, Bellido V: Impact of COVID- 19 lockdown on glycemic control in patients with type 1 diabetes. Diabetes Res Clin Pract, 2020; 166: 108348. 8) Bonora BM, Boscari F, Avogaro A, Bruttomesso D, Fadini GP: Glycaemic control among people with type 1 diabetes during lockdown for the SARS-CoV-2 outbreak in Italy. Diabetes Ther, 2020; 11: 1-11. 9) Curtis V, Dreibelbis R, Sidibe M, et al: How to set up government-led national hygiene communication campaigns to combat COVID-19: a strategic blueprint. BMJ Glob Health, 2020; 5: e002780. 10) Salari N, Hosseinian-Far A, Jalali R, et al: Prevalence of stress, anxiety, depression among the general popula‑tion during the COVID-19 pandemic: a systematic review and meta-analysis. Global Health, 2020;16: 57. 11) Clemmensen C, Petersen MB, Sørensen TIA: Will the COVID-19 pandemic worsen the obesity epidemic? Nat Rev Endocrinol, 2020 Sep; 16: 469-470.337